文献速递肿瘤 PET/CT核素与放射性配体治疗

新辅助雄激素剥夺治疗对非转移性前列腺癌患者68Ga-PSMA示踪剂摄取的影响

The effect of androgen deprivation therapy on 68Ga-PSMA tracer uptake in non-metastatic prostate cancer patients.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2019-11-15

该回顾性研究分析108例接受新辅助雄激素剥夺治疗(ADT)的非转移性激素初治前列腺癌患者,基线及ADT启动后中位2.9个月行68Ga-PSMA-PET/CT,显示治疗后血清PSA、原发肿瘤SUVmax(SUVp)及转移淋巴结SUVmax(SUVln)均显著下降,提示68Ga-PSMA-PET/CT可作为ADT后的定量影像学手段。

要点

  • ADT后84%患者原发肿瘤PSMA摄取下降,中位降幅66%。
  • Gleason评分7分患者代谢缓解率显著高于其他患者。
  • 15%患者出现疾病进展,8%患者据治疗后PET/CT调整放疗决策。

核心结论

  • ADT导致血清PSA、原发肿瘤SUVmax及转移淋巴结SUVmax显著下降。
  • 68Ga-PSMA-PET/CT可作为新辅助ADT后的定量影像学模态用于激素初治非转移性前列腺癌患者。

研究设计与样本

  • 回顾性分析108例接受新辅助ADT的前列腺癌患者临床数据。
  • 所有患者均有基线68Ga-PSMA-PET/CT,ADT启动后中位2.9个月行第二次扫描。

主要发现

  • 治疗后血清PSA、SUVp及SUVln均显著下降。
  • 91例(84%)患者SUVp下降,中位降幅66%(范围5-100%)。
  • 17例(16%)患者PSMA摄取无变化或升高,中位变化24%(范围0-198%)。
  • Gleason评分7分患者代谢缓解率显著高于其他患者。
  • 疾病进展仅在Gleason评分>7分患者中显著高于Gleason评分7分患者。

关键数值与推荐

  • ADT后PSA反应在ISUP高级别肿瘤患者中最低。
  • 16例(15%)患者出现疾病进展,9例(8%)患者根据治疗后68Ga-PSMA-PET/CT调整放疗决策。

临床怎么用

  • ADT后行68Ga-PSMA-PET/CT可定量评估原发肿瘤及转移淋巴结的PSMA摄取变化。
  • 治疗后68Ga-PSMA-PET/CT结果可能影响部分患者的放疗决策。

局限性

  • 本研究为回顾性分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the effect of neoadjuvant androgen deprivation treatment (ADT) on prostate-specific membrane antigen (PSMA) tracer uptake demonstrated in 68Ga-PSMA-positron emission tomography (PET/CT) in non-metastatic hormone-naïve prostate cancer (PC) patients. MATERIALS AND METHODS: The clinical data of 108 PC patients who received neoadjuvant ADT were retrospectively analyzed. All patients had a baseline 68Ga-PSMA-PET/CT scan, and a second scan was delivered median of 2.9 months after the initiation of ADT. The maximum standardized uptake value (SUVmax) of primary tumor (SUVp) and metastatic lymph nodes (SUVln) as well as PSA response were assessed between pre- and post-ADT 68Ga-PSMA-PET/CT scans. RESULTS: There were significant decreases in posttreatment serum PSA, SUVp, and SUVln. A decrease in SUVp was seen in 91 patients (84%) with a median value of 66% (range, 5-100%), while 17 patients (16%) had no change in or an increase in PSMA tracer uptake with a median value of 24% (range, 0-198%). Patients with Gleason score (GS) of 7 had significantly higher metabolic response rates compared to other patients. The disease progression was significantly higher only in patients with GS > 7 disease compared to GS 7 disease. The PSA response to ADT was the lowest in patients with ISUP high-grade tumors. A total of 16 patients (15%) had progressive disease, and in 9 patients (8%), radiotherapy decisions were modified according to posttreatment 68Ga-PSMA-PET/CT scans. CONCLUSIONS: The current study includes the largest number of patients analyzed to date and demonstrates that ADT causes a significant decrease in serum PSA values and SUVp and SUVln. The authors demonstrate that 68Ga-PSMA-PET/CT may be used as a quantitative imaging modality after neoadjuvant ADT in hormone-naïve non-metastatic PC patients.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Onal C, Guler OC, Torun N, et al. The effect of androgen deprivation therapy on 68Ga-PSMA tracer uptake in non-metastatic prostate cancer patients. Eur J Nucl Med Mol Imaging. 2019. PMID: 31732768. doi:10.1007/s00259-019-04581-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。